Most of us have been sitting around a bit more over the past year than usual—we don't have to tell you why. It's no secret that it might be taking a toll on your body. No, not the potential extra ...

The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard ...